|Bid||43.00 x 900|
|Ask||43.19 x 1400|
|Day's range||41.76 - 46.49|
|52-week range||19.51 - 73.72|
|Beta (5Y monthly)||1.66|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Shares of Arrowhead Pharmaceuticals (NASDAQ: ARWR) are up by 49.9% as of 11:35 a.m. EDT on Wednesday, after rising by as much as 51.1% earlier today. Investors are bidding up shares of the biopharmaceutical company today following the release of interim data from a phase 2 clinical trial for one of its pipeline candidates, ARO-AAT. Arrowhead Pharma is developing ARO-AAT as a treatment for liver disease associated with alpha-1 antitrypsin deficiency (AATD).
Today we will run through one way of estimating the intrinsic value of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR...
If you want to know who really controls Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), then you'll have to look at the...